M

Morehouse School of Medicine | Clinical Research Centre

Research site
(Unclaimed)
Location
720 Westview Drive South West, Atlanta, Georgia, United States of America
Site insights

Top conditions

Heart Failure (12 trials)

COVID-19 (7 trials)

Cardiovascular Diseases (7 trials)

Heart Diseases (5 trials)

Atherosclerosis (2 trials)

Top treatments

Aspirin
Montelukast
Metformin
Guselkumab
Aldosterone
Rivaroxaban
Fluticasone
Crizanlizumab
Empagliflozin
Ivermectin

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

12 of 52
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Guselkumab Dose 3
Drug: Ustekinumab

The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejec...

Active, not recruiting
Heart Failure With Preserved Ejection Fraction
Obesity
Other: Placebo
Drug: Tirzepatide
Status recently updated

This study is open to adults, aged 18-75 years, with moderate to severe Crohn's disease.The purpose of this study is to find out whether BI 706321 co...

Enrolling
Active, not recruiting
Crohn Disease
Drug: ustekinumab
Drug: Placebo

The ASPREE Cancer Endpoint Study (ACES), an ancillary study of the ASPirin in the Prevention of Events in the Elderly (ASPREE) Study, will allow for...

Active, not recruiting
Cancer
Drug: Aspirin
Drug: Placebo

The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical mea...

Enrolling
Parkinson's Disease
Drug: BIA 28-6156 60 mg
Drug: BIA 28-6156 10 mg

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

This is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for partic...

Enrolling
Early Detection of Cancer
Cancer
Device: Multi-Cancer Early Detection Test

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Enrolling
Solid Tumor
Malignant Neoplasm
Drug: nab-sirolimus

This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary...

Active, not recruiting
COVID-19
Other: Placebo
Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Open Label Crossover Vaccination period)

This protocol describes a randomized, open-label study to evaluate the safety and tolerability of single-dose intravenous (IV) oritavancin diphosphat...

Enrolling
Acute Bacterial Skin and Skin Structure Infection
Drug: Oritavancin

Trial sponsors

M

Morehouse School of Medicine (10 trials)

Duke University logo

Duke University (6 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems